Table 2.
Pearson correlation between changes in HbA1c and systolic BP or body weight in each eGFR subgroup after 24 weeks of treatment with dapagliflozin at a dosage of 10 mg/d
| Subgroup | HbA1c<0 | HbA1c≥0 | Total |
|---|---|---|---|
| eGFR≥90 ml/min per 1.73 m2 | |||
| Correlationa | r=−0.07; P=0.19 | ||
| Systolic BP <0 | 244 (47.6) | 77 (10.7) | 421 (58.2) |
| Systolic BP ≥0 | 243 (33.6) | 41 (5.7) | 284 (39.3) |
| Total | 587 (81.2) | 118 (16.3) | 705 (97.5) |
| Correlationa | r=0.04; P=0.29 | ||
| Body weight <0 | 477 (66.0) | 86 (11.9) | 563 (77.9) |
| Body weight ≥0 | 110 (15.2) | 32 (4.4) | 142 (19.6) |
| Total | 587 (81.2) | 118 (16.3) | 705 (97.5) |
| eGFR≥60 to <90 ml/min per 1.73 m2 | |||
| Correlationa | r=−0.01; P=0.08 | ||
| Systolic BP <0 | 536 (42.8) | 164 (13.1) | 700 (56.0) |
| Systolic BP ≥0 | 430 (34.4) | 95 (7.6) | 525 (42.0) |
| Total | 966 (77.2) | 259 (20.7) | 1225 (97.9) |
| Correlationa | r=0.15; P<0.001 | ||
| Body weight <0 | 781 (62.4) | 194 (15.5) | 975 (77.9) |
| Body weight ≥0 | 185 (14.8) | 65 (5.2) | 250 (20.0) |
| Total | 966 (77.2) | 259 (20.7) | 1225 (97.9) |
| eGFR ≥45 to <60 ml/min per 1.73 m2 | |||
| Correlationa | r=−0.01; P=0.88 | ||
| Systolic BP <0 | 84 (33.3) | 58 (23.0) | 142 (56.3) |
| Systolic BP ≥0 | 67 (26.6) | 38 (15.1) | 105 (41.7) |
| Total | 151 (59.9) | 96 (38.1) | 247 (98.0) |
| Correlationa | r=−0.02; P=0.76 | ||
| Body weight <0 | 129 (51.2) | 75 (29.8) | 204 (81.0) |
| Body weight ≥0 | 22 (8.7) | 21 (8.3) | 43 (17.1) |
| Total | 151 (59.9) | 96 (38.1) | 247 (98.0) |
Numbers and proportions of patients with a reduction in HbA1c, systolic BP, or body weight (<0) or an increase in these parameters (≥0) during 24 weeks of treatment with dapagliflozin in each eGFR subgroup are shown. Numbers and percentages reported are proportions of the total number of patients in each eGFR category. Proportions do not add to 100%, because a few patients had no baseline or week 24 HbA1c, systolic BP, or body weight data recorded. HbA1c, hemoglobin A1c.
Correlation indicates the correlation between changes in HbA1c and changes in systolic BP or changes in HbA1c and changes in body weight during 24 weeks of treatment with dapagliflozin in each eGFR subgroup.